Operator: Good day, and thank you for standing by. Welcome to the Evaxion Biotech Q2 Results Call. At this time, all participants are in a listen-only mode.
Received regulatory clearance in Australia to initiate phase 2b trial of lead cancer therapy EVX-01 targeting melanomaCompleted recruitment for Phase 1/2a clinical trial for EVX-02 with all patients receiving